US 12,297,434 B1
Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof
Yiqun Che, Beijing (CN); Junhao Wei, Beijing (CN); and Xinyu Han, Beijing (CN)
Assigned to Beijing Friendship Hospital, Capital Medical University, Beijing (CN)
Filed by Beijing Friendship Hospital, Capital Medical University, Beijing (CN)
Filed on Aug. 8, 2024, as Appl. No. 18/797,746.
Int. Cl. C12N 15/113 (2010.01); A61K 31/519 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01)
CPC C12N 15/1137 (2013.01) [A61K 31/519 (2013.01); A61K 31/7105 (2013.01); C12Y 207/01091 (2013.01); C12Y 301/04012 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A composition for treating diffuse large B cell lymphoma comprising a reagent for reducing an expression of sphingomyelin phosphodiesterase 1 (SMPD11 and/or sphingosine kinase 1 (SPHK11 and a Bruton's tyrosine kinase (BTK inhibitor; wherein
the reagent is short hairpin ribonucleic acid (shRNA) with a nucleotide sequence as shown in SEQ ID NO.6; and
the BTK inhibitor is zebutinib.